OSAKA, Japan, Oct. 11, 2019 /PRNewswire/ -- Shionogi & Co., Ltd. (Head Office: Osaka; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today announced that it has entered into a new license agreement with Hsiri Therapeutics, Inc. (Head Office:

SHANGHAI, Oct. 11, 2019 /PRNewswire/ -- Kangpu Biopharmaceuticals announced today that it has successfully completed a first-in-human phase I single ascending dose (SAD) clinical study of KPG-818 conducted in the United States.

EDEN PRAIRIE, Minn., Oct. 10, 2019 /PRNewswire/ -- MIVI Neuroscience, Inc. today announced the appointment of Fred Moll, MD as Chairman of its Board of Directors. Dr. Moll has founded or co-founded multiple innovative medical device companies, and has served on numerous boards throughout his career. Dr. Moll is currently the Chi

SEOUL, South Korea, Oct. 10, 2019 /PRNewswire/ -- Mezzion Pharma Co. Ltd. (140410: KOSDAQ) today announces that on Tuesday, October 8, 2019, Mezzion conducted the Type C meeting with the FDA in Silver Spring, Maryland. The purpose of the Type C meeting was to receive FDA guidance on Mezzion's NDA submi

PALO ALTO, Calif., Oct. 10, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced that the first patients have been treated in the DAZZLE pivotal study of Kodiak's anti-VEGF antibody biopolymer conjugate, KSI-301, in patients with

VAUGHAN, ON, Oct. 10, 2019 /PRNewswire/ - CannTrust Holdings Inc. ("CannTrust" or the "Company", TSX: TRST, NYSE: CTST) today is providing a status update in accordance with its obligations under the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders ("NP 12-203"), which require the Company to provide bi-weekly upda

TEL AVIV, Israel, Oct. 10, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (NASDAQ: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today an update on its planned merger with Destiny Biosciences Global Corp. ("Destiny").

WASHINGTON, Oct. 10, 2019 /PRNewswire/ -- House Appropriations Chairwoman Nita Lowey (D-NY), who announced that she will not seek re-election in 2020, has been a tireless champion for our nation's children and public health who will be greatly missed in Congress. Chairwoman Lowey is a longtime leader in the fight against tobacco who has pus

BETHESDA, Md., Oct. 10, 2019 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into a settlement with the SEC.

TAMPA, Fla., Oct. 10, 2019 /PRNewswire/ -- Canavation Product Group ("Canavation"), a recently formed Delaware company, announced today that it has acquired the consumer products division of Teewinot Life Sciences ("Teewinot"). Terms of the deal were not publicly disclosed. Canavation is rapidly entering the cannabinoid consum